Entered Beta-testing Phase for Updated Proprietary My-Cam Cardiac Event Monitor

Entered Beta-testing Phase for Updated Proprietary My-Cam Cardiac Event Monitor

Updates to provide device improvements while maintaining the innovative core-functionality of CBSC’s state-of-the-art cardiac event monitor  

ESCONDIDO, CA / ACCESSWIRE / December 14, 2021 / CB Scientific, Inc. (OTC PINK: CBSC) (“CBSC” or the “Company”) announced today that the company has entered the Beta testing phase for its updated My-Cam cardiac event monitoring device. The updated design provides improved power consumption, enhanced lead wire shielding, improved signal quality, and a more cost-effective part sourcing while maintaining its core functionality of being a state-of-the-art auto-trigger device.

As demand for the My-Cam device continues to grow throughout CB Scientific’s subsidiaries and partners, CBSC’s commitment to the manufacturing process, both domestically and internationally, will ensure that the company will be able to meet customer demand throughout the current supply chain crisis and beyond. The company anticipates that upon the completion of successful Beta testing, it will move into Pre-production testing (also known as User Acceptance Testing) in the coming weeks.

As additional new developments occur, CB Scientific, Inc. plans to make timely announcements through press releases and regulatory filings to keep its shareholders, industry participants, and the public markets informed.

About CB Scientific, Inc.
CB Scientific, Inc., through its domestic and international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms provide improved compliance for patients at risk of abnormal heart rhythms, as well as more accurate information for physicians.

Company Contact Information:
Telephone: (888) 225-0870
Email: General Inquiries: info@cbscientificinc.com
Investor Inquiries: Robert Hesse – dorchco.bh@gmail.com
Follow CBSC: TwitterFacebookInstagramLinkedInYouTube, and Newsletter

This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions, and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words “plan,” “expect,” “believe,” and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain financing and regulatory and shareholder approval for anticipated actions.

SOURCE: CB Scientific, Inc.

Looking for quarterly reports?View our financial statements.

Get our news in your inbox!

Join our newsletter and we will send our news directly to you.